CSF1 and neoplasm: In terms of immunotherapy, past data has shown that interrupting the actions of cluster of differentiation 73 (CD73), macrophage colony stimulating factor 1 (CSF1) or osteopontin (SPP1) on partially mesenchymal cells, a cellular intermediates of the EMT process, could reverse the immunosuppressive tumour niche [136,142,143].